巨细胞病毒肝炎患儿的听力损伤及更昔洛韦的疗效研究

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (8): 926-929.

巨细胞病毒肝炎患儿的听力损伤及更昔洛韦的疗效研究

徐志伟, 汪洪娇, 陈均亚, 陈益平

温州医学院附属儿童医院感染科, 温州325027, 浙江

收稿日期:2008-06-19 修回日期:2008-07-11 出版日期:2008-08-26 发布日期:2020-10-12
作者简介:徐志伟, 男, 硕士, 副主任医师, 研究方向:儿童感染性疾病。Tel:0577-88816173　E-mail:xuzw1971@sina.com

Clinical investigation of hearing impairment in cytomegalovirus hepatitis and the curative effect of ganciclovir

XU Zhi-wei, WANG Hong-jiao, CHEN Jun-ya, CHEN Yi-ping

Department of Infectious Disease, Children's Hospital Affiliated to Wenzhou Medical College, Wenzhou 325027, Zhejiang, China

Received:2008-06-19 Revised:2008-07-11 Online:2008-08-26 Published:2020-10-12

摘要/Abstract

摘要： 目的:分析巨细胞病毒(CMV)肝炎患儿的听力损伤情况, 探讨更昔洛韦对CMV 肝炎的听力损伤疗效。方法:103例CMV 肝炎患儿随机分为治疗组(65例)和对照组(38例)。治疗组使用更昔洛韦, 辅以护肝利胆等对症治疗, 对照组仅使用护肝利胆等对症治疗。定期检查血常规、生化常规、血CMV-pp65及尿CMV-DNA, 检测脑干听觉诱发电位(ABR)。结果:治疗组患儿治疗前后CMVpp65、CMV-DNA 阳性率之间差异具有统计学意义(P<0.01);对照组治疗前后CMV-pp65、尿CMVDNA阳性率变化差异无统计学意义(P>0.05)。103例CMV 肝炎患儿治疗前ABR 测试, 听力损伤27耳(13.1%)。其中治疗组65例, 听力损伤17耳(13.08%), 对照组38例听力损伤10耳(13.16%), 更昔洛韦治疗后1年, 治疗组听力损伤15耳(11.54%), 对照组听力损伤17耳(22.37%), 两组相比, 听力损伤率差异有统计学意义(P<0.05)。结论:部分CMV 肝炎患儿存在听力损伤, 更昔洛韦治疗能使患儿血CMV-pp65及尿CMV-DNA 阴转, 降低其听力损伤发病率。

关键词: 巨细胞病毒, 听力损伤, 脑干听觉诱发电位

Abstract: AIM:To analyze the hearing impairment rate of cytomegalovirus (CMV)hepatitis and explore the curative effect of ganciclovir.METHODS: 103 cases of CMV hepatitis patients were randomly divided into treatment group (65 cases)and control group (38 cases).Treatment group used Ganciclovir, supplemented symptomatic treatment, the control group used only symptomatic treatment.The blood, biochemical routine, levels of blood CMV-pp65and urine CMVDNA were determined regularly, and the brain stem auditory evoked potential (ABR)was detected.RESULTS: The positive rate of CMV-pp65, CMV-DNA of patients before and after treatment in treatment group had significant difference (P<0.01);The changes of positive rate of CMV-pp65and urine CMV-DNA before and after treatment in control group had no significant difference (P>0.05).The ABR of 103 cases of CMV hepatitis patients was tested before treatment, 27 ears were hearing impairment (13.1%).There were 17 ears hearing impairment (13.08%)in treatment group 65 cases patients, and 10ears hearing impairment (13.16%)in control group 38 cases patients, after one yearwith ganciclovir treatment, 15 ears were hearing impairment (11.54%)in treatment group and 17 ears were hearing impairment (22.37%)in control group.Compared with the two groups, the rate of hearing impairment had significant difference (P<0.05). CONCLUSION:There are the hearing impairment in part of children with CMV hepatitis, after Ganciclovir treatment the blood CMV-pp65and urine CMV-DNA in patients were negative and the incidence of hearing impairment was decreased.

Key words: cytomegalovirus, hearing impairment, brain stem auditory evoked potential

中图分类号:

徐志伟, 汪洪娇, 陈均亚, 陈益平. 巨细胞病毒肝炎患儿的听力损伤及更昔洛韦的疗效研究[J]. 中国临床药理学与治疗学, 2008, 13(8): 926-929.

XU Zhi-wei, WANG Hong-jiao, CHEN Jun-ya, CHEN Yi-ping. Clinical investigation of hearing impairment in cytomegalovirus hepatitis and the curative effect of ganciclovir[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(8): 926-929.

参考文献 13

[1]	Retiè re C, Prod'homme V, Imbert-Marcille BM, et al. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1proteins:a tool to study the fine specificity of the antiviral response[J].J Virol, 2000, 74(9):3948-3952.
[2]	Fowler KB, Dable AJ, Boppana SB, et al.Newborn hearing screening :will children with hearing loss caused by congenital cytomegalovirus infection be missed[J] ? J Pediatr, 1999, 135(1):60-64.
[3]	Dahle AJ, Fowler KB, Wright JD, et al.Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus[J].J Am Acad Audiol, 2000, 11(5): 283-290.
[4]	Fowler KB, McCollister FP, Dohle AJ, et al.Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegaloirus infection[J].J Pediatr, 1997, 130(4):624-630.
[5]	Dunduroz R, Akin R, Okutan V, et al.Acquired cytomegalovirus infection in infants.A case successfully treated with ganciclovir[J].Presse Med, 1997, 26(21):1000-1001.
[6]	Fischler B.Ganciclovir treatment in infants with cytomegalovirus infection and cholestasis[J].J Pediatr Gastroenterol Nutr, 2002, 34(2):154-157.
[7]	朴春姬.更昔洛韦治疗婴儿巨细胞病毒性肝炎疗效观察[J].中国优生与遗传杂志, 2007, 15(1):109.
[8]	MichaelsMG, Greenberg DP, Sabo DL, et al.Treatment of children with congenital cytomegalovirus infection with · 928· Chin J Clin Pharmacol Ther 2008 Aug;13(8)ganciclovir[J].Pediatr Infect Dis J, 2004, 23(1):88-89.
[9]	方峰, 董永绥.巨细胞病毒和巨细胞病毒感染的诊断[J].中华儿科杂志, 1999, 37(7):397-399.
[10]	Williamson WD, Demmler GJ, Percy AK, et al.Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection[J].Pediatrics, 1992, 90(6): 862-866.
[11]	Sugiura S, Yoshikawa T, Nishiyama Y, et al.Detection of herpesvirus DNAs in perilymph obtained from patients with sensorineural hearing loss by real-time polymerase chain reaction[J].Laryngoscope, 2004, 114(12):2235-2238.
[12]	Williamson WD, Demmler GJ, Percy AK, et al.Progressive hearing loss in infants with asymp-tomatic congenital cytomegalovirus infection[J].Pediatrics, 1992, 90(6): 862-866.
[13]	Vancikova Z, Kucerova T, Pelikan L, et al.Perinatal cytomegalovirus hepatitis:to treat or not to treat with ganciclovir[J].J Paediatr Child Health, 2004, 40(8):444-448.

[1]	戚林玲, 刘寿荣. 丙酚替诺福韦在乙肝母婴阻断中的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(5): 578-582.
[2]	孟时, 王中群. 人类免疫缺陷病毒相关性肺动脉高压研究进展[J]. 中国临床药理学与治疗学, 2022, 27(12): 1431-1440.
[3]	陶承静, 刘寿荣, 程晓仙, 胡健女, 白秀丽, 张素英, 赵春, 左中宝. 替诺福韦不同产后停药时间对乙型肝炎病毒标志物、病毒学以及生化学指标的影响[J]. 中国临床药理学与治疗学, 2021, 26(10): 1146-1152.
[4]	李倩, 吕红, 刘岳, 石佳. 心血管手术围术期抗纤溶治疗的有效性及安全性[J]. 中国临床药理学与治疗学, 2021, 26(7): 830-835.
[5]	王娜娜, 谭效锋, 马涛, 程玉生. 慢性肺曲霉菌病的治疗现状及展望[J]. 中国临床药理学与治疗学, 2021, 26(2): 217-222.
[6]	李红鹏, 张柳, 李庆云. COVID-19免疫相关发病机制与免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2020, 25(11): 1288-1294.
[7]	王纬璐, 茅以诚, 朱依谆. 自噬在病毒性肺炎中的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(11): 1315-1320.
[8]	穆鑫, 赵颖, 张兰, 崔一民, 张永祥, 杜冠华. 我国治疗新冠肺炎药物临床研究现状浅析[J]. 中国临床药理学与治疗学, 2020, 25(8): 869-877.
[9]	张正付，李萌，王佳楠. 新型冠状病毒肺炎临床试验的受试者保护[J]. 中国临床药理学与治疗学, 2020, 25(4): 421-425.
[10]	刘奇，夏帅，姜世勃. 抗新型冠状病毒2019-nCoV新药的研发[J]. 中国临床药理学与治疗学, 2020, 25(3): 241-245.
[11]	崔诚，么雪婷，涂思琪，谢洁恩，李海燕，刘东阳. 硫酸羟氯喹的临床药理学研究进展[J]. 中国临床药理学与治疗学, 2020, 25(2): 221-226.
[12]	罗艺，蒋志伟. 新冠肺炎应急临床试验设计中的统计学考虑[J]. 中国临床药理学与治疗学, 2020, 25(2): 121-125.
[13]	蓝巧帅，夏帅，周洁，王茜，陆路. 新型冠状病毒SARS-CoV-2感染治疗中的“老药新用”[J]. 中国临床药理学与治疗学, 2020, 25(2): 126-134.
[14]	胡克. 新型冠状病毒肺炎：问题与困惑[J]. 中国临床药理学与治疗学, 2020, 25(2): 141-143.
[15]	黄馨仪，郭飞，曾祥昌，欧阳冬生. 短链脂肪酸作为信号分子在肠道炎症中的研究进展[J]. 中国临床药理学与治疗学, 2019, 24(11): 1293-1299.